Recent Price Decline Creates An Attractive Entry Point For Halozyme
Sep. 16, 2014 10:35 AM ET | About: Halozyme Therapeutics, Inc. (HALO), Includes: BAX
Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)
Summary •Halozyme witnessed a price fall of 4.36% on the approval of collaborative drug HyQvia with Baxter. •The share price fall was further fueled by Underperform reiteration by Jefferies Group. •Halozyme has strong technology, revenue generators, sound financials and deep pipeline going forward. •The current price fall is a good entry point to go long on Halozyme